| Cat. No. | Species | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|
| IL2-H8210 | Human | Biotinylated Human IL-12B&IL-12A Heterodimer Protein, His,Avitag™&Flag Tag |  |
|
|
| IL2-H4210 | Human | Human IL-12B&IL-12A Heterodimer Protein, His Tag&Flag Tag |  |
|
|
Human IL-12 R beta 1, Fc Tag (Cat. No. ILB-H5255) captured on CM5 chip via Anti-human IgG Fc antibodies surface can bind Human IL-12B&IL-12A Heterodimer Protein, His Tag&Flag Tag (Cat. No. IL2-H4210) with an affinity constant of 2.06 nM as determined in a SPR assay (Biacore T200) (Routinely tested).
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Thalidomide | NSC-66847; NSC-527179; K-17; VP-02 | Approved | Celgene Corp | Talizer, Thalidomide Celgene, Thalidomide Pharmion, Synovir, Thalomid, Thaled | Japan | Leprosy, Lepromatous | Fujimoto Pharmaceutical | 1982-01-01 | HIV Infections; Spondylitis, Ankylosing; Myelodysplastic Syndromes; Idiopathic Pulmonary Fibrosis; Multiple Myeloma; HIV Wasting Syndrome; Erythema Nodosum; Leprosy, Lepromatous; Carcinoma, Hepatocellular | Details |
| Ustekinumab | CNTO-1275; C-340; AVT-04 | Approved | Janssen Global Services Llc | Stelara | Mainland China | Plaque psoriasis | Janssen-Cilag International Nv | 2009-01-15 | Polymyositis; Solid tumours; Liver Cirrhosis, Biliary; Dermatomyositis; Inflammatory Bowel Diseases; Multiple Sclerosis; Lupus Erythematosus, Systemic; Psoriasis; Takayasu Arteritis; Arthritis, Psoriatic; Colitis, Ulcerative; Crohn Disease; Plaque psoriasis; Dermatitis, Atopic | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| Ustekinumab Biosimilar (NeuClone/Serum Institute of India) | Phase 1 Clinical | Neuclone, Serum Institute Of India | Autoimmune Diseases | Details | |
| IL-12 gene therapy (Methodist Hospital) | Phase 2 Clinical | Methodist Hospital System | Triple Negative Breast Neoplasms | Details | |
| Lisofylline | BL-194; CT-1501R; A-802710 | Phase 3 Clinical | Cti Biopharma Corp | Diabetes Mellitus, Type 1; Rejection of organ transplantation | Details |
| NHS-IL-12 | M-9241; MSB-0010360 | Phase 2 Clinical | Emd Serono Inc, Merck Serono, National Cancer Institute | Neoplasms | Details |
| INO-9012/Human papillomavirus vaccine (VGX Pharmaceuticals) | INO-3112; INO-9012/VGX-3100; VGX-3100/INO-9012 | Phase 2 Clinical | University Of Pennsylvania | Head and Neck Neoplasms; Squamous Cell Carcinoma of Head and Neck; Uterine Cervical Neoplasms | Details |
| ONCR-177 | ONCR-177 | Phase 1 Clinical | Oncorus | Liver Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Skin Neoplasms; Triple Negative Breast Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Melanoma | Details |
| AK101 | AK-101 | Phase 2 Clinical | Zhongshan Akeso Biopharma Co Ltd | Psoriasis; Arthritis, Psoriatic; Colitis, Ulcerative; Crohn Disease; Plaque psoriasis | Details |
| Interleukin-12 gene therapy (OncoSec Medical) | pIL-12; DNA IL-12 | Phase 2 Clinical | Inovio | Breast Neoplasms; Mycosis Fungoides; Melanoma; Carcinoma, Hepatocellular; Lymphoma, T-Cell, Cutaneous; Lung Neoplasms; Colorectal Neoplasms; Prostatic Neoplasms; Lymphoma, Mantle-Cell; Ovarian Neoplasms; Hepatitis B; Pancreatic Neoplasms; Triple Negative Breast Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Merkel Cell; Stomach Neoplasms; Esophageal Neoplasms; Head and Neck Neoplasms | Details |
| Recombinant human anti-IL12 antibody (Bio-Thera Solutions) | BAT-2206 | Phase 3 Clinical | Bio-Thera Solutions Ltd | Autoimmune Diseases; Psoriasis; Arthritis, Psoriatic; Colitis, Ulcerative; Crohn Disease; Plaque psoriasis | Details |
| Ustekinumab biosimilar(DM Bio) | DA-3115; DMB-3115 | Phase 3 Clinical | Meiji Seika Pharma Co Ltd, Dong-A Pharmaceutical Co Ltd | Psoriasis | Details |
| Apilimod mesilate | LAM-002; LAM-002A; STA-5326; STA-5326-mesylate | Phase 2 Clinical | Lam, Synta | Coronavirus Disease 2019 (COVID-19); Arthritis, Rheumatoid; Psoriasis; Lymphoma, Non-Hodgkin; Crohn Disease; Immunologic Deficiency Syndromes | Details |
| T3011疱疹病毒（深圳市亦诺微医药） | Phase 2 Clinical | Shenzhen Yinuowei Pharmaceutical Technology Co Ltd | Head and Neck Neoplasms; Solid tumours; Esophageal Neoplasms; Breast Neoplasms; Neoplasm Metastasis; Melanoma; Carcinoma, Non-Small-Cell Lung | Details | |
| Ustekinumab Biosimilar (qyuns) | QX-001-S; QX-001S | Phase 3 Clinical | Jiangsu Quanxin Biomedical Co Ltd | Psoriasis; Plaque psoriasis | Details |
| Ustekinumab biosimilar(Formycon) | FYB-202 | Phase 3 Clinical | Formycon | Immune System Diseases; Psoriasis | Details |
| Ustekinumab biosimilar (BioFactura) | BFI-751 | Phase 1 Clinical | BioFactura Australia Pty Ltd | Psoriasis | Details |
This web search service is supported by Google Inc.
A-Z
